Aurgalys Team
Selected Customers
Home
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]
 

Nov. 25th, 2015: Aurgalys initiates coverage on Sensorion [Euronext: ALSEN]

novembre 25, 2015

Paris- Evry, France, Nov. 25th, 2015 – Aurgalys, a global provider for life sciences and healthcare companies through corporate finance, business development and interim management services, initiates coverage on Sensorion.

« Sensorion is a biopharmaceutical company, specializing in the development of drugs for inner ear disorders. Its lead product, SENS-111, is a Phase II-ready drug candidate for the treatment of vertigo and tinnitus. The company announced positive Phase Ib results confirming the safety and tolerability of SENS-111 in healthy volunteers. The company also develops SENS-218 for vestibular lesions. SENS-218 is a molecule from the setron class, a well known family of antiemetic drugs. A pilot study already conducted in patients with a different molecule of the same class demonstrated efficacy in preserving vestibular functions. SENS-218 is in late preclinical and a Phase II study could start as early as H2-2016. Our target price for Sensorion as of November 24th, 2015, is €10.03/share »

You can download the coverage initiation report at the following link:

Comments are closed.